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Abstract
Drugs are primary weapons for reducing malaria in human populations. However emergence of resistant parasites has
repeatedly curtailed the lifespan of each drug that is developed and deployed. Currently the most effective anti-malarial is
artemisinin, which is extracted from the leaves of Artemisia annua. Due to poor pharmacokinetic properties and prudent
efforts to curtail resistance to monotherapies, artemisinin is prescribed only in combination with other anti-malarials
composing an Artemisinin Combination Therapy (ACT). Low yield in the plant, and the added cost of secondary anti-
malarials in the ACT, make artemisinin costly for the developing world. As an alternative, we compared the efficacy of oral
delivery of the dried leaves of whole plant (WP) A. annua to a comparable dose of pure artemisinin in a rodent malaria
model (Plasmodium chabaudi). We found that a single dose of WP (containing 24 mg/kg artemisinin) reduces parasitemia
more effectively than a comparable dose of purified drug. This increased efficacy may result from a documented 40-fold
increase in the bioavailability of artemisinin in the blood of mice fed the whole plant, in comparison to those administered
synthetic drug. Synergistic benefits may derive from the presence of other anti-malarial compounds in A. annua. If shown to
be clinically efficacious, well-tolerated, and compatible with the public health imperative of forestalling evolution of drug
resistance, inexpensive, locally grown and processed A. annua might prove to be an effective addition to the global effort to
reduce malaria morbidity and mortality.
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Introduction
Malaria is among the most prevalent infectious diseases in the
developing world, imposing a vast burden of mortality and
perpetuating cycles of poverty. In 2009, the World Health
Organization (WHO) estimated that 225 million cases of malaria
occurred, with .780,000 deaths [1]. In spite of recent advances in
our understanding of this parasite, efforts to prevent transmission
have remained largely unchanged for over a century. Though
malaria vaccines hold future promise, vector control and
chemotherapy remain the primary weapons for reducing the
burden of disease in individuals and populations. Artemisinin, in
the form of Artemisinin-based Combination Therapy (ACT), is
currently the best treatment option against those malaria parasites
that have evolved resistance to drugs such as chloroquine [2].
Moreover, artemisinin (AN) and its derivatives have also been
shown to affect a number of viruses, a variety of human cancer cell
lines [3,4], several neglected tropical parasitic diseases including
schistosomiasis [5], leishmaniasis [6,7], New- and Old-World
trypanosomiases [8], and some livestock diseases [9].
Current artemisinin production requires its extraction from the
cultivated herb Artemisia annua L., which is a ‘‘generally regarded as
safe’’ (GRAS) herb suitable for human consumption [10].
However, considerable production costs and inadequate availabil-
ity of artemisinin limit its present usefulness in the campaign
against malaria [11]. Until very recently [12], de novo chemical
synthesis of artemisinin was neither practical nor cost-effective.
The best plant cultivars yield only ca. 1.5% artemisinin, and
agricultural yields seldom exceed 70 kg/ha [13]. The drug is
solvent-extracted from plant material, crystallized, and typically
used for semi-synthesis of artemisinic derivatives. Although A.
annua is relatively easy to grow in temperate and subtropical
climates, low yields of artemisinin lead to relatively high costs for
isolation and purification of the drug [14]. Because of this
shortcoming, plant scientists have focused their efforts on pro-
ducing cultivars of A. annua with higher artemisinin crop yield [15].
Transgenic production schemes are also underway [16,17].
Meanwhile, a worldwide shortage fails to meet the need to treat
malaria, not to mention those other diseases against which
artemisinin holds such promise [2].
One means of reducing the cost of production would be to limit
the amount of post-harvest processing by using the whole plant
(WP). We wondered whether omitting the extraction step, by using
whole plant A. annua directly as the source of artemisinin, might
prove efficacious in an experimental murine model. In a previous
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study, we showed that mice fed dried WP material had about
40 times more artemisinin in their bloodstream than mice that
were fed a corresponding amount of pure drug [10]. This amount
exceeded by eight fold the minimum concentration of serum
artemisinin (10 mg/L) required against P. falciparum [18]. This
suggested that the active ingredients were delivered faster, and in
greater quantity, from whole plant treatments than from pure drug
treatments. We further hypothesized that because of the combi-
nation of parasite-killing substances normally present in the plant
(artemisinin and flavonoids) [19,20], a synergism among these
constituent compounds might render whole plant consumption as
a form of ACT.
We thus sought to determine whether WP A. annua can kill
malaria parasites in vivo using a rodent malaria model. Plasmodium
chabaudi is an excellent model for the most deadly of the human
parasites, P. falciparum, because both species demonstrate prefer-
ence for mature erythrocytes as opposed to reticulocytes that are
favored by other human and rodent malaria parasites [21,22].
Rodent malaria models are invaluable for studying modes and
mechanisms of resistance to antimalarial compounds [23].
Demonstrating parasite killing using this inexpensive and resilient
treatment could be an important first step in establishing a novel
therapy based on WP A. annua for treatment of human malaria.
Furthermore, it may help to identify other complementary and/or
synergistic anti-malarial compounds within the plant.
Results and Discussion
We found conclusive evidence that orally ingested, powdered
dried leaves of whole plant A. annua kills malaria parasites more
effectively than a comparable dose of pure drug. In our primary
analysis we used dried A. annua leaves containing 14.8 mg
artemisinin per gram of dried leaves and compared parasitemia
over time in mice treated with either low-dose, whole plant A.
annua (WPLO), low-dose, pure drug artemisinin (ANLO), or placebo
(CON). Only 24 hr after treatment, dead parasites (with
condensed dark pigment) were observed in mice treated with
WPLO; 30 hours after treatment, parasitemia was ,0.001%
(Figure 1). Mice treated with WPLO showed significantly lower
parasitemia than those treated with ANLO from 12 to 72 hours
post-treatment (Figure 2). Mice treated with ANLO did not show
significant difference in parasitemia from those administered
a placebo at any time point.
In a subsequent dose-response analysis, we added high-dose
comparison groups, ANHI and WPHI. Each of the four treatment
groups experienced significantly lower parasitemia than the
control mice (Figure 3). All mice treated with WPLO responded
strongly in the first 24 hr following gavage, showing the lowest
level of parasitemia at 30 hours post-gavage; only 3 of 26 WPLO-
treated mice (12%) had parasitemia $3%. However, 36 hours
after gavage, 38% of the WPLO-treated mice were above this
threshold. Notably, treatment with WPLO was just as effective in
reducing parasitemia as was treatment with ANHI for the first
72 hours post treatment (Figure 3). Thereafter, WPLO-treated
mice had significantly higher parasitemia. Although the suppres-
sion of parasitemia was significant in the three treatment groups
after a single dose treatment, low dose WPLO resulted in faster
recrudescence than either WPHI or ANHI (Figure 3), suggesting
that multiple treatments at this dose would be necessary for
a curative effect. Considering that a normal course of ACT
treatment for human malaria currently requires several doses,
spread over several days, a similar regime may also be effective in
the case of lower dose WP administration. Pharmacokinetics will
be needed to determine serum levels of the drug. No differences
between the WPHI and ANHI groups were detected after
treatment. This is consistent with the short half-life seen in the
pure drug in human patients and the prescribed need for multiple
doses per day for several days [24].
Figure 1. Giemsa stained blood smears from mice showing
erythrocytes infected with P. chabaudi, 30 hours after treat-
ment with (A) WPLO (24 mg/kg whole plant delivered artemi-
sinin), (B) ANLO (24 mg/kg pure drug artemisinin), and (C)
Placebo control.
doi:10.1371/journal.pone.0052746.g001
Whole Plant A. annua as an Antimalarial Therapy
PLOS ONE | www.plosone.org 2 December 2012 | Volume 7 | Issue 12 | e52746
Although the precise mechanism of its anti-malarial activity
remain unproven, artemisinin is suspected (like other drugs,
including chloroquine) to interfere with heme detoxification,
a crucial requirement for parasite survival in erythrocytes.
Plasmodium parasites digest hemoglobin, producing heme as
a byproduct. Free heme molecules are toxic, so parasites sequester
it in the form of hemozoin polymers in unique digestive vacuoles.
Artemisinin is a sesquiterpene lactone with a crucial endoperoxide
bridge [25], and in the presence of heme, this bridge is broken,
thereby releasing free radicals harmful to the parasite [26].
The empirical evidence for increased anti-malarial activity of
WP relative to AN might be explained by differential bio-
availability of the artemisinic compounds. Weathers et al. showed
that mice treated with a WP equivalent of 1.2 mg/kg AN reached
their highest concentration of artemisinin in the blood (87 mg/L)
30 min after gavage, whereas mice treated with AN did not reach
their the maximum concentration (74 mg/L) until much later
($60 min) [10]. Moreover, poor solubility and high metabolic
breakdown of artemisinin by hepatic and intestinal cytochrome P
enzymes (CYP P450 and CYP3A4) may reduce its bioavailability
when administered in pure form [27]. Infusions made from whole
plant A. annua showed marked inhibition of the intestinal and
hepatic CYP enzymes by flavonoids and/or other compounds [9].
Hence, inhibition of metabolic enzymes correlates with greater
bioavailability of artemisinin, which is consistent with our findings
that WP demonstrates greater parasite killing activity than
a comparable pure drug treatment.
Whole plant (WP) A. annuamay also have enhanced antimalarial
activity due to synergism among particular plant compounds and
artemisinin [9,28,29]. Among these compounds are many
flavonoids, of which at least six (artemetin, casticin, chrysosplene-
tin, chrysosplenol-D, cirsilineol, and eupatorin) are of interest for
Figure 2. P. chabaudi parasitemia of three treatment groups across all experimental replicates: low-dose whole plant A. annua (WPLO,
N=26 containing 24 mg/kg in planta artemisinin, and low-dose pure drug (ANLO, N=20) containing 24 mg/kg pure artemisinin, and
placebo control (CON, N=23) which received only mouse chow. Dark lines indicate average parasitemia by treatment type. Lighter lines
show individual mouse trajectories. Shaded regions indicate the 95% confidence interval for the means calculated based on normality assumptions.
Dashed vertical line indicates time of treatment.
doi:10.1371/journal.pone.0052746.g002
Figure 3. Dose comparisons of WP and AN treatments from the third replicate of data: WPLO (N=6) and WPHI (N=6) received 24 mg/
kg and 120 mg/kg in planta artemisinin, respectively; ANLO (N=5) and ANHI (N=6) received 24 mg/kg and 120 mg/kg pure
artemisinin, respectively. Placebo control (CON, N= 6) received only mouse chow. Dark lines indicate average parasitemia by treatment type.
Lighter lines show individual mouse trajectories. Shaded regions indicate the 95% confidence interval for the means calculated based on normality
assumptions. Dashed vertical line indicates time of treatment.
doi:10.1371/journal.pone.0052746.g003
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their antimalarial roles. The synergism between artemisinin and
these flavonoids may be due to their ability to potentiate the
activity of artemisinin. When each of these six flavonoids was
combined individually with artemisinin, the IC50 of AN against P.
falciparum decreased by 20–50%, demonstrating an apparent
synergy between the sesquiterpene lactone, artemisinin, and those
six methoxylated flavonoids [19,20]. The precise mechanism of
flavonoids in activating artemisinin is not fully understood,
however it has been reported that A. annua methoxylated
flavonoids enhance the formation of the artemisinin-heme
complex [30], which increases the release of free radicals.
Two other major A. annua flavonoids, myricetin and quercetin,
are known to inhibit mammalian thioredoxin reductase, which is
critical for cellular redox control [31]. Thioredoxin reductase is
also essential for the P. falciparum erythrocytic stage [32]; therefore,
inhibition of this parasite enzyme by myricetin and quercetin may
work in synergy with artemisinin against P. falciparum [33].
In addition to the bioavailability and potentiation attributes of
WP, there are other compounds in A. annua that may act to reduce
parasitemia independent of artemisinin. Liu et al (1992) reported
the antimalarial activity of several A. annua flavonoids delivered in
vitro as isolated compounds, in the absence of artemisinin [20].
Moreover, antimalarial activity has been documented for related
plant species that do not produce artemisinin [34]. Among the
compounds in A. annua not yet fully investigated are more than
a dozen other sesquiterpenes, some of which have shown promise
for killing parasites in rodent models [28].
Determining the mechanisms for increased efficacy of WP will
require further investigation, but it seems certain that the
constituent compounds contained within A. annua comprise
a complex set of interactions and synergies yet to be described.
Given the complex nature of the plant and its many components,
WP may not necessarily be considered a simple monotherapy.
While the temptation might be to consider WP as merely an
alternative delivery mechanism for artemisinin, our results strongly
indicate that WP is unique and may represent an innovative
combination therapy. We refer to this as a plant Artemisinin
Combination Therapy (pACT). A pACT can be distinguished from
other combinational therapies where the drug components do not
necessarily work synergistically because their combinations are
artificially contrived. The pACT comprises a biologically complex
entity, in which the combinations are result of evolutionary
processes that would have attributes of redundancy and resiliency
that make combination therapies selectively advantageous to
simple monotherapies. Refinements of these combinations by
evolutionary processes ensures they are robust.
The novelty of the WP pACT cannot be overemphasized as
there is a common misconception that this therapy has been tested
previously. It has not. The WP therapy tested in the present study
should not be confused with tea or infusion therapy. Whole plant
A. annua (WP) tested here against murine malaria, uses the plant
leaves, dried under controlled conditions and ingested by the host.
Such a preparation of A. annua has never been tested against
malaria parasites (in humans, mice or otherwise).
Because A. annua has long been used to make tea to treat fever in
Asia [35], several investigators have proposed to re-establish the
use of A. annua tea for rapid treatment of malaria [2,36]. These teas
have major shortcomings. First, large volumes of tea must be
consumed over short periods to ensure adequate ingestion of drug,
a nontrivial matter considering the bitter taste of the tea, especially
for pediatric patients. Moreover, while a 5 min boiling water
extraction yields about 90% of the plant’s artemisinin [36], this is
not an effective process for extracting key flavonoids [20]. Our
analysis of hot water tea extracts following the optimized protocol
described by van der Kooy and Verpoorte [36], showed loss of
about 99% of some of the original flavonoids that reportedly
synergize with artemisinin [37].
Not only does WP differ from teas and infusions in terms of its
efficacy and pharmaceutical properties, but also because of its
preparation, it can be carefully controlled and preserved. We
previously proposed development of a new form of anti-malarial
therapy based on dried, encapsulated A. annua leaves as an
inexpensive, dose-controlled, rapid delivery of the drug to treat
uncomplicated cases of malaria and other neglected tropical
diseases for which artemisinin has been shown to be effective [10].
Dosage can be controlled because dried WP A. annua can be
homogenized and assayed for artemisinin content prior to
encapsulation. Capsule size and number can be adjusted based
on artemisinin content and patient weight.
Our purpose in the present study was to determine whether this
‘‘generally regarded as safe’’ (GRAS) herb [38] is effective in
killing malaria parasites in vivo. Extrapolating appropriate human
dosage from experimental evidence in mouse models will require
additional investigation, however it is generally accepted that this
extrapolation does not scale linearly with respect to body mass.
Better indicators that allow for allometry include use of total body
surface area [39] and/or take full consideration of physiochemical
properties of the drugs and species involved [40]. As an example of
this non-linear relationship, we can look to the results from ANLO
treatment administered to mice in our study. ANLO mice received
a dose of 24 mg/kg, which exceeds the current WHO single
therapeutic dose (20 mg/kg) for treating human malaria, however,
in our study this dose of pure drug had very little effect against
mouse malaria parasites. This is most likely due to metabolic
differences and rates of uptake of oral drug between mice and
humans.
Single oral dosages of AN proven effective against human P.
falciparum malaria range from 100–500 mg [41], which corre-
sponds to 6–33 grams of WP assuming a 1.5% artemisinin
content. Assuming an average tablet size of 1 gram, delivery of
a comparable dose of WP seems plausible. However, our data
suggests that WP requires a smaller overall amount of artemisinin
since even the WPLO effectively reduced malaria after just a single
dose. Moreover, it is important to bear in mind that while WPLO
was the lowest concentration in our study, it does not necessarily
represent a minimum effective dose.
Notwithstanding challenges to be overcome and further re-
search needed, our preliminary investigations hold great promise
for easing the burden of high cost and limited availability currently
confronting use of artemisinin-based semi-synthetic derivatives.
While production costs for pharmaceuticals are not generally
publically available, it is possible to estimate potential savings
associated with using WP vs. AN by looking to the estimated
efficiencies of processing AN from the plant. Kindermans et al
[42] estimate the yield for extraction and purification of drug from
A. annua to be 50–80% efficient. This is consistent with general
understanding of downstream processing costs wherein product
losses increase with the number of unit operations (unit ops) [43].
All things being equal (e.g. artemisinin content for a given
cultivar), this would suggest a 20–50% savings realized by forgoing
the extraction and purification steps, as would be the case for
production of WP. An example of the steps involved in production
of AN from whole plant is provided by de Vries et al., and
compared with steps for producing WP (Figure 4). Current
production of AN by extraction from A. annua has seven more unit
ops than the one associated with direct use of the whole plant, and
this net loss in efficiency translates to higher costs per product unit
(Figure 4). Given the multiplicative principle of downstream
Whole Plant A. annua as an Antimalarial Therapy
PLOS ONE | www.plosone.org 4 December 2012 | Volume 7 | Issue 12 | e52746
processing, even if each processing step has relatively high
efficiency, the overall efficiency will be less. For example, even if
each of the seven additional steps for production of AN was 95%
efficient, the overall efficiency would be merely 69.8%, which
means that less than three quarters of the starting material is
realized as drug. Such a loss translates to higher cost for the
delivered drug. This simple analysis does not even consider the
additional costs for reagents, labor, and energy that are required
for processing the extract (Figure 4), which de Vries et al. [44]
estimated may comprise up to 22.9% of the total manufacturing
costs. This 22.9% represents additional cost savings for the use of
WP because those inputs are no longer required.
And while our data are far from representing a clinical trial,
they do provide preliminary indications that the WP therapy
requires a far smaller dose than the corresponding amount of pure
artemisinin. Indeed, our experiments indicate that a dose of WP
has a five-fold increase in anti-malarial activity over that of the
corresponding amount of AN. This increased activity per unit of
plant mass not only affects the dosing regimen but also has
profound economic impacts if the WP approach should prove
useful on a large scale to treat human malaria.
Much work remains to determine feasibility and efficiency of
bringing whole plant A. annua into the arsenal in the fight against
malaria. Among the challenges to be faced are some botanical
obstacles, not the least of which is that this plant readily outcrosses,
making it difficult to maintain high artemisinin content in the
plant using seed saving methods which are standard agricultural
practice in the developing world. Moreover, to date all efforts at
improving the A. annua crop have focused on plant breeding and
agricultural methods to maximize artemisinin content and in so
doing to increase efficiencies and drive down costs. The use of the
whole plant as therapy may represent a paradigm shift in this
regard, since it may well be the case that effectiveness of WP is not
wholly dependent on artemisinin content. New plant breeding
strategies would have to be considered to optimize plant
performance and maximize efficacy. The potential for an in-
expensive malaria therapy that by its very nature possesses great
resilience to parasite resistance, makes this investment of effort well
worthwhile.
Conclusions
We have demonstrated that orally delivered WP A. annua is an
effective means of killing malaria parasites in a mouse model. An
edible WP A. annua treatment approach could significantly increase
the number of patients treated and at significantly less cost. In fact,
our results suggest that the WP treatment is a more efficient
delivery mechanism than the purified drug, which is both costly
and inefficient. Because AN has such broad potential therapeutic
power against many infectious agents [3], our approach would
dramatically reduce the cost of healthcare not only in developing
countries, but also in more developed nations. Furthermore, use of
A. annua could be implemented locally: a plan for plant cultivation,
processing, and drug content validation was described in our
earlier report [10]. This, in turn, could provide a broad
socioeconomic stimulus for developing countries bearing the
greatest burden of malaria transmission.
Methods
Plant material
Artemisia annua L. (SAM cultivar; voucher MASS 00317314)
containing 1.4860.06% AN (dry weight) as determined by GC-
MS was used in this study. To obtain adequate amounts of leafy
biomass, plants were grown in soil either in greenhouses, culture
rooms, or growth chambers under continuous light to maintain
vegetative growth. Plants were propagated by cuttings to insure
that the outcrossing characteristics of A. annua did not result in
genetic loss of AN content. When the plants reached about 0.5–
1 m, they were harvested and dried in the light at 25uC for several
days. Leaves were then stripped from stems and pulverized
through a series of brass sieves ending with 600 mm meshed
powder. All dry leafy biomass was pooled, homogenized and then
assayed for AN.
AN was measured using GC-MS by extracting with pentane
(,6 mg/mL) and sonicating for 30 min. Extract was decanted
into glass test tubes and dried under nitrogen gas, then stored at
220uC until analysis. Samples were resuspended in pentane and
transferred to a 1 mL vial with a 100 mL glass insert. A 1 mL
injection into the GC-MS [GC, Agilent 7890A; MS, Agilent
5975C; column, Agilent HP-5MS (30 m60.25 mm60.25 mm)]
used the following oven program: ion source temperature 280uC;
inlet 250uC; initial temperature of 125uC for 1 min, then ramp to
300uC at 5uC/min, for a total time of 36 min. Ultrapure helium
was the carrier gas at 1 mL min21. Identification was via NIST
library and purchased AN standard (Sigma-Aldrich Chemical, St.
Louis, MO).
Parasite information
Plasmodium chabaudi ASS (MRA-429) was obtained through the
Malaria Research and Reference Reagent Resource Center
(MR4) as a part of the BEI Resources Repository, NIAID, NIH.
Tubes of blood collected from infected mice, were removed from
liquid nitrogen storage and left at room temperature for
30 minutes. A 100 mL aliquot of the parasite-infected blood was
mixed with 500 mL Dulbecco’s Phosphate Buffered Saline (DPBS).
To activate parasite stocks, two C57BL/6 mice were injected
intraperitoneally (i.p.) with 200 mL of the DPBS mixture. Percent
Figure 4. Comparison of unit operations required for production of extracted AN and production of WP. Extracted AN process is based
on that described by de Vries et al. [45].
doi:10.1371/journal.pone.0052746.g004
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parasitemia was determined in Giemsa-stained thin blood smears
days 3–7 post-infection (p.i.). Seven days after infection, one mouse
was euthanized and cardiac puncture was used to collect blood
into lithium heparin tubes. Infected blood was volumetrically
adjusted by dilution in DPBS to create a 200 mL aliquot of 105
infected erythrocytes for infection into two additional mice for
a second round of activation. The activated parasites were used for
subsequent challenge and drug study. Rodent malaria models
showed differences in the degree of susceptibility among different
strains of mice, as well as age related differences. We used two
mice to draw the standard parasitemia curve in the C57BL/6, 8–
12 weeks male mice. The two mice were inoculated i.p with 105
infected erythrocytes and parasitemia was determined in Giemsa-
stained thin blood smears from day 1 to day 11 p.i. (Figure 1). P.
chabaudi produces a self-limiting infection in laboratory mice, such
that parasites began to appear in the blood smears on day 4 p.i.,
reaching peak of the parasitemia on day 8 p.i. From the standard
parasitemia curve we chose to treat mice on day 6 p.i. when the
parasites commenced the log phase of growth.
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of Massachusetts (Proto-
col# 2011-0015). All efforts were made to minimize suffering of
animals during experimental procedures.
Mouse feeding and drug delivery details. All mouse
experiments used inbred male mice C57BL/6, 12 weeks of age.
For each experimental replicate, an aliquot of 105 infected
erythrocytes was inoculated i.p. into each of 30 mice. For the
first two replicates, mice were randomly divided into three groups
of ten mice per group (ANLO, WPLO, and Control). For the third
replicate, mice were randomly divided into five groups of six mice
per group (ANLO, WPLO, ANHI, WPHI, and Control). Individual
mice were identified by tail markings using permanent marker.
Starting on day 3 p.i., percent parasitemia was determined in
Giemsa-stained thin blood smears from a drop of peripheral blood
obtained from the tail. Mice were observed twice daily for signs of
disease stress. Food and water were introduced ad libitum for the
first five days. On day five, food was withheld for 24 hours, but
water was freely available.
Whole plant (WP) treatment consisted of dried A. annua plant
powder ground and passed through a 0.3 mm sieve, mixed with
water to a final volume of 0.5 mL. Two dosages were used: WPLO
and WPHI. WPLO consisted of 0.5 mL treatment slurry contained
40 mg dry weight (DW) of plant powder, containing 600 mg
artemisinin and corresponding to 24 mg AN/kg live body weight.
WPHI consisted of 0.75 mL treatment slurry contained 200 mg
DW of plant powder, containing 3000 mg artemisinin and
corresponding to 120 mg AN/kg live body weight.
Pure drug (AN) treatment consisted of artemisinin purchased
from Sigma Aldrich freshly dissolved in DMSO and pulverized
mouse chow. Two dosages were used, ANLO and ANHI. ANLO
consisted of a slurry containing 600 mg AN dissolved in 60 uL
DMSO mixed with water and 40 mg powdered mouse chow to
final volume of 0.5 mL. ANLO consisted of a slurry containing
3000 mg AN dissolved in 60 uL DMSO mixed with water and
200 mg powdered mouse chow to final volume of 0.75 mL.
Placebo control (CON) consisted of 60 mL DMSO, mixed with
water and 40 mg powdered mouse chow to a final volume of
0.5 mL. Delivery of the appropriate 0.5 mL treatment/control
was performed immediately after dose preparation by oral-gastric
gavage into mice using a feeding needle (18G, curved, 2’’, and
2.25 pall diameter). Food and water were introduced ad libitum
after gavage. Percent parasitemia was determined every 24 hours
in Giemsa-stained thin blood smears from days 3–6 p.i., then every
six hours for 48 hours post gavage, and again on 24 hour intervals
for days 9–11 p.i. All mice were euthanized on day 11 p.i. via
asphyxiation in a CO2 chamber followed by cervical dislocation.
The experiment was repeated three times.
Statistical analysis
We fit linear mixed models to estimate and compare the average
parasitemia for each treatment group at each measured time
point. Including a random intercept for individual mice allowed us
to adjust for repeated observations on the same mouse. The
primary analysis compared CON, WPLO and ANLO treatment
groups to assess statistically significant parasitemia differences in
these groups at each time point (see Figure 2). For the primary
analysis, data from all three replicates were used. A secondary
dose-response analysis compared the CON, WPLO, WPHI, ANLO,
and ANHI treatment groups at all measured time points (see
Figure 3). For the secondary analysis only data from the third
replicate were used.
For each model, 10,000 Markov chain Monte Carlo (MCMC)
samples were drawn from the posterior distributions of the average
parasitemia levels for each treatment group at each time point.
Then, 95% confidence interval endpoints for a particular para-
sitemia level were established at the 2.5th and 97.5th quantiles of
the MCMC samples for that parameter. An estimated difference
between two groups was declared ‘‘significant’’ if the 95%
confidence interval for the difference did not cover zero. Analyses
were conducted using the statistical software R v2.15 and the lmer
package [45], Graphics were produced using the ggplot2 package
[46,47].
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